| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on September 8, 2004
Accepted on April 1, 2005
Proteomics and Protein Markers |
1 Department of Physiology, Queen's University, Kingston, Ontario, Canada
2 Department of Pathology, Queen's University, Kingston, Ontario, Canada
3 Department of Emergency Medicine, Queen's University, Kingston, Ontario, Canada
* To whom correspondence should be addressed. E-mail: iscoes{at}post.queensu.ca.
Background: Detection of skeletal muscle injury is hampered by a lack of commercially available assays for serum markers specific for skeletal muscle; serum concentrations of skeletal troponin I (sTnI) could meet this need. Moreover, because sTnI exists in two isoforms, slow (ssTnI) and fast (fsTnI), corresponding to slow- and fast-twitch muscles, respectively, it could provide insight into differential injury/recovery of specific fiber types. The purpose of this study was to investigate whether the two isoforms of sTnI and their modified forms are present in the blood of patients with various skeletal muscle disorders.
Methods: Serial serum samples were obtained from 25 patients with various skeletal muscle injuries. Serum proteins were separated by a modified sodium dodecyl sulfate-polyacrylamide gel electrophoresis protocol followed by Western blotting for sTnI with monoclonal antibodies specific to ssTnI and fsTnI.
Results: We observed (a) intact and, in some cases, degraded sTnI products; (b) evidence of posttranslational modifications in addition to proteolysis; and (c) differential detectability of both skeletal isoforms in the same patient.
Conclusions: It is possible to monitor both sTnI isoforms; this could lead to the development of new diagnostic assays for skeletal muscle damage.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  J. D. Vassallo, E. B. Janovitz, D. M. Wescott, C. Chadwick, L. J. Lowe-Krentz, and L. D. Lehman-McKeeman Biomarkers of Drug-Induced Skeletal Muscle Injury in the Rat: Troponin I and Myoglobin Toxicol. Sci., October 1, 2009; 111(2): 402 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Rabek, C. E. Hafer-Macko, J. K. Amaning, J. H. DeFord, V. L. Dimayuga, M. A. Madsen, R. F. Macko, and J. Papaconstantinou A Proteomics Analysis of the Effects of Chronic Hemiparetic Stroke on Troponin T Expression in Human Vastus Lateralis J Gerontol A Biol Sci Med Sci, August 1, 2009; 64A(8): 839 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Pritt, D. G. Hall, J. Recknor, K. M. Credille, D. D. Brown, N. P. Yumibe, A. E. Schultze, and D. E. Watson Fabp3 as a Biomarker of Skeletal Muscle Toxicity in the Rat: Comparison with Conventional Biomarkers Toxicol. Sci., June 1, 2008; 103(2): 382 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Simpson and S. Iscoe Cardiorespiratory failure in rat induced by severe inspiratory resistive loading J Appl Physiol, April 1, 2007; 102(4): 1556 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sheng, D. Chen, and J. E. Van Eyk Multidimensional Liquid Chromatography Separation of Intact Proteins by Chromatographic Focusing and Reversed Phase of the Human Serum Proteome: Optimization and Protein Database Mol. Cell. Proteomics, January 1, 2006; 5(1): 26 - 34. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
